A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants
Completed · Phase 1 · NCT06742086
Conditions: Healthy Volunteer
At a glance
- Research payments reported, 2025
- $587,351
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 72
About the trial
- Sponsor
- AbbVie
- Tested
- Venetoclax (drug)
- Dates
- Started 2024-12-19; completion 2025-10-08
- Results posted
- Not yet
The objective of this study is to assess the bioavailability (BA) of venetoclax new high drug load hot melt extrusion-03 (HME-03) tablet formulation at two different tablet strengths relative to the commercial venetoclax tablet formulation under high-fat conditions in healthy female volunteers. Additionally, this study will assess the potential food effect on the BA of the venetoclax HME-03 tablet at the highest dosage strength.
From ClinicalTrials.gov, last updated 2025-10-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $587,351 in research payments for this study in 2025 (10 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ppd Phase I Clinic $586,171
- $1,180
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.